Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/34964
Full metadata record
DC FieldValueLanguage
dc.contributor.authorQuan, Stuart F-
dc.contributor.authorWeaver, Matthew D-
dc.contributor.authorCzeisler, Mark É-
dc.contributor.authorBarger, Laura K-
dc.contributor.authorBooker, Lauren A-
dc.contributor.authorHoward, Mark E-
dc.contributor.authorJackson, Melinda L-
dc.contributor.authorLane, Rashon I-
dc.contributor.authorMcDonald, Christine F-
dc.contributor.authorRidgers, Anna-
dc.contributor.authorRobbins, Rebecca-
dc.contributor.authorVarma, Prerna-
dc.contributor.authorWiley, Joshua F-
dc.contributor.authorRajaratnam, Shantha M W-
dc.contributor.authorCzeisler, Charles A-
dc.date2023-
dc.date.accessioned2024-01-30T23:22:56Z-
dc.date.available2024-01-30T23:22:56Z-
dc.date.issued2023-12-31-
dc.identifier.citationMedRxiv : the Preprint Server for Health Sciences 2023-12-31en_US
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/34964-
dc.description.abstractObstructive sleep apnea (OSA) is associated with COVID-19 infection. Fewer investigations have assessed OSA as a possible risk for the development of Post-Acute Sequelae of SARS-CoV-2 infection (PASC). In a general population, is OSA associated with increased odds of PASC-related symptoms and with an overall definition of PASC? Cross-sectional survey of a general population of 24,803 U.S. adults. COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence rates for a wide variety of persistent (> 3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models adjusted for demographic, anthropometric, comorbid medical and socioeconomic factors, OSA was associated with all putative PASC-related symptoms with the highest adjusted odds ratios (aOR) being fever (2.053) and nervous/anxious (1.939) respectively. Elastic net regression identified the 13 of 37 symptoms most strongly associated with COVID-19 infection. Four definitions of PASC were developed using these symptoms either weighted equally or proportionally by their regression coefficients. In all 4 logistic regression models using these definitions, OSA was associated with PASC (range of aORs: 1.934-2.071); this association was mitigated in those with treated OSA. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9%. In a general population sample, OSA is associated with the development of PASC-related symptoms and a global definition of PASC. A PASC definition requiring the presence of 3 or more symptoms may be useful in identifying cases and for future research.en_US
dc.language.isoeng-
dc.subjectCOVID-19en_US
dc.subjectLong COVIDen_US
dc.subjectObstructive Sleep Apneaen_US
dc.subjectPASCen_US
dc.subjectPost-Acute Sequelae of SARS-CoV-2 infectionen_US
dc.titleAssociation of Obstructive Sleep Apnea with Post-Acute Sequelae of SARS-CoV-2 infection (PASC).en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleMedRxiv : the Preprint Server for Health Sciencesen_US
dc.identifier.affiliationDivision of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA.;Division of Sleep Medicine, Harvard Medical School, Boston, MA.en_US
dc.identifier.affiliationInstitute for Breathing and Sleepen_US
dc.identifier.affiliationSchool of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.;Institute for Breathing and Sleep, Austin Health, Heidelberg, Victoria, Australia.en_US
dc.identifier.affiliationDepartment of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.;Department of Respiratory and Sleep Medicine, Austin Health, Heidelberg, Victoria, Australia.;Faculty of Medicine, Monash University, Melbourne Australia.en_US
dc.identifier.affiliationFrancis Weld Peabody Society, Harvard Medical School, Boston, MA.;School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Melbourne, Victoria, Australia.;en_US
dc.identifier.doi10.1101/2023.12.30.23300666en_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0002-9474-7679en_US
dc.identifier.orcid0000-0003-3578-336Xen_US
dc.identifier.orcid0000-0003-3100-7347en_US
dc.identifier.orcid0000-0001-8547-7331en_US
dc.identifier.orcid0000-0001-7262-2632en_US
dc.identifier.orcid0000-0003-4976-8101en_US
dc.identifier.orcid0000-0002-0612-1466en_US
dc.identifier.orcid0000-0001-6481-3391en_US
dc.identifier.orcid0000-0003-1360-9387en_US
dc.identifier.orcid0000-0003-0288-2505en_US
dc.identifier.orcid0000-0001-5408-1625en_US
dc.identifier.orcid0000-0002-0271-6702en_US
dc.identifier.orcid0000-0001-7527-8558en_US
dc.identifier.orcid0000-0002-7408-1849en_US
dc.identifier.pubmedid38234859-
item.languageiso639-1en-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

58
checked on Dec 25, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.